Half Year 2025 Orion Oyj Earnings Call Transcript
Key Points
- Orion Oyj (ORINY) reported a 27% increase in net sales, reaching EUR416.5 million for Q2 2025.
- Operating profit grew by 59%, with an operating profit margin of 25%.
- The company received FDA approval and CHMP recommendation for darolutamide in combination with ADT for metastatic hormone-sensitive prostate cancer.
- Orion Oyj (ORINY) expanded its research pipeline, including a new agreement with Glykos for antibody drug conjugates and a partnership with Shilpa for recombinant albumin.
- The Easyhaler portfolio is projected to exceed EUR300 million in annual sales, indicating strong growth potential.
- Fermion division experienced slightly lower sales due to capacity constraints.
- Simdax and Trexan prices are decreasing due to generic competition, impacting revenue.
- There is uncertainty in the second half of the year regarding Nubeqa sales and R&D expenses, leading to a wide guidance range.
- Potential US pharma tariffs could impact sales, though the exact effect remains uncertain.
- R&D expenses are expected to increase in the second half of the year, potentially affecting profitability.
Hello from sunny Helsinki and welcome to Orion's Q2 2025 earnings conference call and webcast. My name is Tuukka Hirvonen. I'm the Head of Investor relations here at Orion.
In a few moments, our CEO and President, Liisa Hurme, will present the results and key events from the past quarter followed by the opportunity to ask questions from Liisa and also from our CFO, Rene Lindell, who is here today also.
We will start taking questions first from the conference call lines and then afterwards we will turn to the webcast. So you all have the opportunity to type in your questions using the chat function of the webcast. Kindly state your name and the organization you are representing before asking your question.
And also, to be noted that recording of this webcast will be available on Orion's website later this afternoon and also to our Finnish speaking viewers information that also a Finnish interview of the CEO, Liisa Hurme will also be available on Orion's website later this afternoon.
But without any further
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
